<PAGE>

================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB

           |X| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

                For the quarterly period ended September 30, 2003

                                       OR

          |_| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

            For the Transition Period from ___________ to ___________

                        Commission File Number: 333-64430

                             EMERGENSYS CORPORATION
             (Exact name of Registrant as specified in its charter)

            Delaware                                  33-0820923
(State or other jurisdiction of            (I.R.S. Employer Identification No.)
incorporation or organization)

                        400 Jean-Lesage Blvd., Suite 045
                             Quebec, Quebec G1K, 8W1
          (Address of principal executive offices, including zip code)

                                 (418) 380-8911
              (Registrant's telephone number, including area code)

                      Medical Licensing International Corp.
                   (Former Name if Changed Since Last Report)

        Check whether the  Registrant  (1) has filed all reports  required to be
filed by Section 13 or 15(d) of the  Securities  Exchange Act of 1934 during the
preceding 12 months,  and (2) has been subject to such filing  requirements  for
the past 90 days. Yes [X] No [ ]

        The number of shares of the Registrant's  common  stock  outstanding  at
December 17 2003, was 31,124,005.

      Transitional Small Business Disclosure Format:      Yes [ ]       No [X]

================================================================================

<PAGE>


                             EMERGENSYS CORPORATION
               SEPTEMBER 30, 2003 QUARTERLY REPORT ON FORM 10-QSB

                                TABLE OF CONTENTS

<TABLE>
<CAPTION>

                                                                                    PAGE
<S>                                                                                 <C>
               Special Note Regarding Forward Looking Statements .....................3

                                 PART I FINANCIAL INFORMATION

Item 1.        Financial Statements ..................................................4
Item 2.        Management's Discussion and Analysis
               of Financial Condition and Results of Operations/Plan of Operation....16
Item 3         Controls and Procedures...............................................19

                                   PART II OTHER INFORMATION

Item 2.        Changes in Securities and Use of Proceeds.............................20
Item 4.        Submission of Matters to a Vote of Security Holders...................20
Item 5.        Other Information.....................................................21
Item 6.        Exhibits and Reports on Form 8-K......................................21
</TABLE>

                                       2

<PAGE>


                SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

        To the extent that the information presented in this Quarterly Report on
Form  10-QSB for the quarter  ended  September  30,  2003,  discusses  financial
projections,  information  or  expectations  about our  products or markets,  or
otherwise   makes   statements   about  future  events,   such   statements  are
forward-looking.  We are making these forward-looking  statements in reliance on
the safe harbor  provisions of the Private  Securities  Litigation Reform Act of
1995.   Although  we  believe   that  the   expectations   reflected   in  these
forward-looking  statements  are based on  reasonable  assumptions,  there are a
number of risks and  uncertainties  that could  cause  actual  results to differ
materially from such forward-looking  statements.  These risks and uncertainties
are described,  among other places in this Quarterly  Report,  in  "Management's
Discussion and Analysis of Financial Condition and Results of Operations/Plan of
Operation".

        In addition,  we disclaim any obligations to update any  forward-looking
statements to reflect events or  circumstances  after the date of this Quarterly
Report.  When considering such  forward-looking  statements,  you should keep in
mind the risks  referenced  above and the other  cautionary  statements  in this
Quarterly Report.


                                        3

<PAGE>

                         PART I - FINANCIAL INFORMATION

<TABLE>
<CAPTION>

                       ITEM 1. FINANCIAL STATEMENTS PAGE
<S>                                                                                 <C>
        Balance Sheet as of September 30, 2003 (unaudited)............................5

        Statements of Operations  for the three and nine months ended  September
        30,2003 and 2002 (unaudited) and for the period from
        December 22, 1995 (inception) to September 30, 2003 (unaudited)...............6

        Statements  of Cash Flows for the three and nine months ended  September
        30,2003 and 2002 (unaudited) and for the period from
        December 22, 1995 (inception) to September 30, 2003 (unaudited)..............7-8

        Notes to Financial Statements (unaudited).....................................9
</TABLE>


                                       4

<PAGE>

                                                          EMERGENSYS CORPORATION
                      (FORMERLY KNOWN AS MEDICAL LICENSING INTERNTATIONAL CORP.)
                                                   (A DEVELOPMENT STAGE COMPANY)
                                                                   BALANCE SHEET
                                                  SEPTEMBER 30, 2003 (UNAUDITED)
--------------------------------------------------------------------------------

<TABLE>
<CAPTION>
                                      ASSETS
<S>                                                                 <C>
CURRENT ASSETS
    Cash                                                            $   586,911
    Prepaid expenses                                                    140,000
                                                                    -----------

       Total current assets                                             726,911

PROPERTY AND EQUIPMENT                                                   70,000
PURCHASED SOFTWARE                                                      780,000
SOFTWARE LICENSE RIGHTS                                               1,598,500
                                                                    -----------

             TOTAL ASSETS                                           $ 3,175,411
                                                                    ===========

                     LIABILITIES AND SHAREHOLDERS' EQUITY

CURRENT LIABILITIES
    Accounts payable and accrued expenses                           $    50,000
                                                                    -----------

       Total current liabilities                                         50,000
                                                                    -----------

COMMITMENTS AND CONTINGENCIES

SHAREHOLDERS' EQUITY
    Preferred stock, $0.0001 par value
       20,000,000 shares authorized
       no shares issued or outstanding                                       --
    Common stock, $0.0001 par value
       80,000,000 shares authorized
       10,824,005 shares issued and outstanding                           1,082
    Common stock committed, 20,300,000 shares                         3,198,500
    Additional paid-in capital                                        1,940,983
    Deficit accumulated during the development stage                 (2,015,154)
                                                                    -----------

          Total shareholders' equity                                  3,125,411
                                                                    -----------

             TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY             $ 3,175,411
                                                                    ===========
</TABLE>

   The accompanying notes are an integral part of these financial statements.

                                        5

<PAGE>

                                                          EMERGENSYS CORPORATION
                      (FORMERLY KNOWN AS MEDICAL LICENSING INTERNTATIONAL CORP.)
                                                   (A DEVELOPMENT STAGE COMPANY)
                                                        STATEMENTS OF OPERATIONS
     FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2003 AND 2002 (UNAUDITED)
                         AND FOR THE PERIOD FROM DECEMBER 22 1995 (INCEPTION) TO
                                                  SEPTEMBER 30, 2003 (UNAUDITED)
--------------------------------------------------------------------------------

<TABLE>
<CAPTION>
                                                                                                             For the
                                                                                                           Period from
                                                                                                           October 19,
                                                                                                               1995
                              For the Three Months Ended               For the Nine Months Ended         (Inception) to
                                     September 30,                           September 30,                September 30,
                           --------------------------------        --------------------------------        ------------
                               2003                2002                2003                2002                2003
                           ------------        ------------        ------------        ------------        ------------
<S>                        <C>                 <C>                 <C>                 <C>                 <C>
OPERATING EXPENSES
   General and
     administrative
     expenses              $     54,451        $    159,171        $     78,730        $    721,560        $    837,399
                           ------------        ------------        ------------        ------------        ------------

LOSS FROM CONTINUING
   OPERATIONS                   (54,451)           (159,171)            (78,730)           (721,560)           (837,399)

LOSS FROM
   DISCONTINUED
   OPERATIONS                        --            (368,686)           (266,189)         (1,652,575)         (4,413,523)
                           ------------        ------------        ------------        ------------        ------------

NET LOSS                   $    (54,451)       $   (527,857)       $   (344,919)       $ (2,374,135)       $ (5,250,922)
                           ============        ============        ============        ============        ============

BASIC AND DILUTED
   LOSS PER SHARE
     Continuing
       operations          $         --        $      (0.01)       $      (0.00)       $      (0.04)
     Discontinued
       operations                    --               (0.02)              (0.02)              (0.09)
                           ------------        ------------        ------------        ------------

TOTAL LOSS PER SHARE       $         --        $      (0.03)       $      (0.02)       $      (0.13)
                           ============        ============        ============        ============

   WEIGHTED-AVERAGE
     COMMON SHARES
     OUTSTANDING             15,464,222          18,679,287          16,358,639          18,620,674
                           ============        ============        ============        ============
</TABLE>

   The accompanying notes are an integral part of these financial statements.


                                      6
<PAGE>

                                                          EMERGENSYS CORPORATION
                      (FORMERLY KNOWN AS MEDICAL LICENSING INTERNTATIONAL CORP.)
                                                   (A DEVELOPMENT STAGE COMPANY)
                                                        STATEMENTS OF CASH FLOWS
               FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2003 AND 2002 (UNAUDITED)
     AND FOR THE PERIOD FROM DECEMBER 22, 1995 (INCEPTION) TO SEPTEMBER 30, 2003
                                                                     (UNAUDITED)
--------------------------------------------------------------------------------

<TABLE>
<CAPTION>
                                                                                              For the
                                                                                             Period from
                                                                                             December 22,
                                                          For the Nine Months Ended              1995
                                                                September 30,               (Inception) to
                                                        ------------------------------       September 30,
                                                           2003                2002             2003
                                                        -----------        -----------        -----------
CASH FLOWS FROM OPERATING ACTIVITIES
<S>                                                     <C>                <C>                <C>
   Net loss from continuing operations                  $   (78,730)       $(2,374,135)       $  (837,399)
   Adjustments to reconcile net loss
     from continuing operations to net
     cash used in operating activities
       Depreciation and amortization                             --              7,058                 --
       Amortization of deferred stock
         compensation                                            --             30,499                 --
       Note discount amortization                                --                 --                 --
       Stock-based compensation expense                          --                 --                 --
       (Increase) decrease in
         Accounts receivable                                 (3,722)           435,500             (3,722)
         Income taxes receivable                                 --                 --                 --
         Deferred tax assets                                     --                 --                 --
         Prepaid assets                                    (140,000)           (18,001)          (140,000)
         Other assets                                            --                 --                 --
       Increase (decrease) in
         Accounts payable and accrued
           expenses                                         (80,185)           (75,355)              (644)
         Deferred revenue                                        --           (270,000)                --
         Accrued income taxes                                    --            (36,125)                --
                                                        -----------        -----------        -----------

Net cash used in continuing operations                     (302,637)        (2,300,559)          (981,765)
Net cash used in discontinued operations                   (264,630)                --         (2,307,739)
                                                        -----------        -----------        -----------

Net cash used in operating activities                      (567,267)        (2,300,559)        (3,289,504)
                                                        -----------        -----------        -----------

CASH FLOWS FROM INVESTING ACTIVITIES
   Purchase of property and equipment                       (70,000)           (15,577)          (128,981)
   Purchase of software                                    (780,000)                --           (780,000)
   Other assets                                                  --                 --            (10,106)
                                                        -----------        -----------        -----------

Net cash used in investing activities                      (850,000)           (15,577)          (919,087)
                                                        -----------        -----------        -----------

</TABLE>

   The accompanying notes are an integral part of these financial statements.

                                      7

<PAGE>


                                                          EMERGENSYS CORPORATION
                      (FORMERLY KNOWN AS MEDICAL LICENSING INTERNTATIONAL CORP.)
                                                   (A DEVELOPMENT STAGE COMPANY)
                                                        STATEMENTS OF CASH FLOWS
               FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2003 AND 2002 (UNAUDITED)
     AND FOR THE PERIOD FROM DECEMBER 22, 1995 (INCEPTION) TO SEPTEMBER 30, 2003
                                                                     (UNAUDITED)
--------------------------------------------------------------------------------

<TABLE>
<CAPTION>
                                                                                              For the
                                                                                             Period from
                                                                                             December 22,
                                                          For the Nine Months Ended              1995
                                                                September 30,               (Inception) to
                                                        ------------------------------       September 30,
                                                           2003                2002             2003
                                                        -----------        -----------        -----------
<S>                                                     <C>                <C>                <C>
CASH FLOWS FROM FINANCING ACTIVITIES
   Proceeds from loan payable                           $        --        $        --        $   120,000
   Repayment of loan payable                                     --                 --           (120,000)
   Issuance of stock in reverse merger                           --                 --          1,494,489
   Issuance of common stock                               1,700,000          1,500,000          3,301,013
                                                        -----------        -----------        -----------

New cash provided by financing activities                 1,700,000          1,500,000          4,795,502
                                                        -----------        -----------        -----------

Net increase (decrease) in cash                             282,733           (816,136)           586,911

CASH, BEGINNING OF PERIOD                                   304,178          1,481,881                 --
                                                        -----------        -----------        -----------

CASH, END OF PERIOD                                     $   586,911        $   665,745        $   586,911
                                                        ===========        ===========        ===========

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
   INCOME TAXES PAID                                    $        --        $    13,000        $    61,000
                                                        ===========        ===========        ===========
</TABLE>


SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES

On September 16, 2003,  the Company  entered into a software  license  agreement
with a Canadian  corporation.  In consideration of the grant of the license, the
Company  committed  to issue  12,900,000  shares  and  1,000,000  shares  of its
restricted common stock to the Canadian  corporation and to certain employees of
the Canadian  company,  respectively.  The shares have been valued at $0.115, or
$1,598,500.


   The accompanying notes are an integral part of these financial statements.

                                       8

<PAGE>

                                                          EMERGENSYS CORPORATION
                      (FORMERLY KNOWN AS MEDICAL LICENSING INTERNTATIONAL CORP.)
                                                   (A DEVELOPMENT STAGE COMPANY)
                                                                        CONTENTS
                                                  SEPTEMBER 30, 2003 (UNAUDITED)
--------------------------------------------------------------------------------


NOTE 1 - ORGANIZATION AND LINE OF BUSINESS

        General

        Since its inception  until the spin-off of its  operating  subsidiary on
        May 5, 2003, Emergensys Corporation, formerly known as Medical Licensing
        International  Corp.,  (the "Company") was known as Molichem  Medicines,
        Inc. and operated as an early stage  pharmaceutical  company  focused on
        the discovery,  development and marketing of pharmaceutical products for
        the treatment of serious respiratory and related conditions.

        The Company conducted these development and commercialization activities
        through its wholly owned subsidiary Molichem R&D, Inc. ("Molichem R&D").
        On May 5, 2003, 100 percent of the stock of MoliChem R&D was transferred
        to Lantibio,  Inc. in exchange for 13,355,282  shares of common stock of
        the Company held by Lantibio, Inc., which were subsequently cancelled by
        the Company,  and a license  agreement  providing  certain rights to the
        intellectual  property  held by MoliChem  R&D. In  connection  with this
        transaction all of the Company's assets and liabilities were transferred
        to MoliChem R&D, after which the Company's  operations consist solely of
        holding a license from  Molichem  R&D, and  maintaining  its status as a
        public reporting entity.

        Molichem R&D, was  incorporated  on December 22, 1995 in North Carolina.
        On January 18,  2001,  Molichem R&D acquired  Cortez  Development,  Ltd.
        ("Cortez") in a reverse  merger in which Molichem R&D was the accounting
        acquirer and Cortez was the legal acquirer.  Cortez was  incorporated on
        July 20,  1998  under  the  laws of the  State  of  Delaware  and had no
        operations  prior to the  reverse  merger.  Cortez  changed  its name to
        Molichem Medicines,  Inc. after completion of the merger.  Subsequent to
        the reverse  merger,  Molichem R&D became a  wholly-owned  subsidiary of
        Molichem Medicines,  Inc. Medical Licensing International,  Inc. changed
        its name to Emergensys Corporation on November 21, 2003.

        License Agreement

        Effective  September  16,  2003,  the  Company  entered  into a Software
        License   Agreement  (the  "License   Agreement")  with  3720161  Canada
        Corporation,  a Canadian  corporation  doing  business under the name of
        Mobilair  Integration  ("Mobilair").  Mobilair is a leading developer of
        technological  solutions  (hardware  and  software)  that  integrate new
        concepts for public safety and security management systems.  The License
        Agreement   provides   the  Company   with  an   exclusive,   worldwide,
        royalty-free,  perpetual license to use, offer and distribute Mobilair's
        software  for public  safety and  security  management  systems  and all
        modifications,  enhancements,  and  replacements  thereof and  additions
        thereto related to the public safety and security market.


                                       9

<PAGE>

                                                          EMERGENSYS CORPORATION
                      (FORMERLY KNOWN AS MEDICAL LICENSING INTERNTATIONAL CORP.)
                                                   (A DEVELOPMENT STAGE COMPANY)
                                                                        CONTENTS
                                                  SEPTEMBER 30, 2003 (UNAUDITED)
--------------------------------------------------------------------------------


NOTE 1 - ORGANIZATION AND LINE OF BUSINESS (CONTINUED)

        License Agreement (Continued)

        The public  safety and security  market is the market  covering  police,
        fire, ambulance and environmental  services provided by federal,  state,
        provincial,  municipal or local public authorities.  In consideration of
        the grant of the License, the Company committed to issue to Mobilair and
        certain  of its  employees,  12,900,000  shares  and  1,000,000  shares,
        respectively,  of its  restricted  common  stock.  The shares  have been
        valued at $0.115, or $1,598,500.

        Effective  September  24,  2003 the  Company's  board of  directors  was
        increased from one to five members and Gilles  Cloutier  resigned as the
        Company's sole executive officer.  Daniel Veilleux,  Louis Lessard, Jean
        Guy Lambert,  and Stuart  Gauld were  appointed as directors to fill the
        vacancies  created  by the  increase  in the size of the  board.  Daniel
        Veilleux was  appointed as the Company's  president and chief  executive
        officer,  Bruno Lemay as the  Company's  treasurer  and chief  financial
        officer and Mario Jacob as the Company's secretary to fill the vacancies
        created by Mr.  Cloutier's  resignation.  Mr.  Veilleux is the  founder,
        principal shareholder and president of Mobilair.

NOTE 2 - DISCONTINUED OPERATIONS

        On May 5, 2003 the  Company  exchanged  100  percent of the stock of its
        wholly owned  subsidiary,  MoliChem R&D, Inc., for 13,355,282  shares of
        the  Company's  stock owned by  Lantibio,  Inc., a company owned by the
        former  President and certain former  shareholders  of the Company.  The
        Company also received a non-exclusive  license (the "License Agreement")
        to develop,  market,  and sell certain products  incorporating  MoliChem
        R&D, Inc.'s compounds Moli56A and Moli56B.

        The License Agreement has a ten year term, provides for annual licensing
        fees of $1.00 payable by the Company on each  anniversary of the License
        Agreement,  a one time  continuation  payment of $500,000 payable on the
        first anniversary of the License Agreement, a one time milestone payment
        of $2,000,000 payable by the Company within 60 days of the approval of a
        product   incorporating  the  technology   encompassed  by  the  License
        Agreement,  and annual royalty  payments equal to 6 percent of net sales
        related to the technology encompassed by the License Agreement.

        In addition,  options to purchase a total of 1,637,114  shares of common
        stock were cancelled in connection with the  transaction.  In connection
        with  the  spin-off,  all of the  assets  and  liabilities  of  MoliChem
        Medicines,  Inc. were transferred to MoliChem R&D, Inc. The Company does
        not expect to incur further costs in connection with the spin-off.

                                       10

<PAGE>

                                                          EMERGENSYS CORPORATION
                      (FORMERLY KNOWN AS MEDICAL LICENSING INTERNTATIONAL CORP.)
                                                   (A DEVELOPMENT STAGE COMPANY)
                                                                        CONTENTS
                                                  SEPTEMBER 30, 2003 (UNAUDITED)
--------------------------------------------------------------------------------


NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

        Basis of Presentation

        The accompanying  financial  statements have been prepared in conformity
        with accounting  principles  generally  accepted in the United States of
        America for interim  financial  information and with the instructions to
        Form 10-QSB and Regulation S-B. Accordingly,  they do not include all of
        the  information  and  footnotes   required  by  accounting   principles
        generally  accepted  in  the  United  States  of  America  for  complete
        financial  statements.  In  the  opinion  of  management,   all  normal,
        recurring adjustments  considered necessary for a fair presentation have
        been included.  The financial  statements  should be read in conjunction
        with the audited financial  statements  included in the Company's annual
        report on Form 10-KSB for the year ended  December 31, 2002. The results
        of  operations  for the nine  months  ended  September  30, 2003 are not
        necessarily  indicative of the results that may be expected for the year
        ended December 31, 2003.

        Going Concern

        The  accompanying  financial  statements  have been  prepared on a going
        concern basis, which assumes continuity of operations and realization of
        assets  and  satisfaction  of  liabilities  in the  ordinary  course  of
        business.  As set forth in Note 2,  following the transfer of assets and
        liabilities to Lantibio, Inc., the Company had no assets or liabilities,
        and  no  revenue  generating   operations.   These  circumstances  raise
        substantial  doubt as to the Company's ability to continue to operate as
        a going concern.

        The Company's  ability to continue as a going concern is dependent  upon
        its ability to obtain additional  financing and initiate operations that
        will ultimately  generate cash flows. The Company plans to pursue equity
        or debt  financing  to fund the  cost of its  basic  infrastructure  and
        future  operations.  In the  event  the  Company  is  unable  to  obtain
        additional financing or generate cash from operations, it might not have
        sufficient funds to permit the Company to continue to operate for a year
        following September 30, 2003.

        Principles of Consolidation

        The  accompanying  financial  statements  include  the  accounts  of the
        Company and its wholly owned subsidiary up to the date of spin-off.  All
        significant  intercompany balances and transactions have been eliminated
        in  consolidation.  Comparative  financial  data  has been  restated  to
        reflect the operating  results of the segment of the Company spun off on
        May 5, 2003 as  operating  results  from  discontinued  operations.


                                       11

<PAGE>
                                                          EMERGENSYS CORPORATION
                      (FORMERLY KNOWN AS MEDICAL LICENSING INTERNTATIONAL CORP.)
                                                   (A DEVELOPMENT STAGE COMPANY)
                                                                        CONTENTS
                                                  SEPTEMBER 30, 2003 (UNAUDITED)
--------------------------------------------------------------------------------


NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

        Development Stage Enterprise

        The Company is a  development  stage  company as defined in Statement of
        Financial Accounting Standards ("SFAS") No. 7, "Accounting and Reporting
        by Development  Stage  Enterprises."  The Company is devoting all of its
        present efforts to establishing its new business and to fundraising, and
        its planned  principal  operations  have not yet  commenced.  All losses
        accumulated  since  inception  have  been  considered  as  part  of  the
        Company's development stage activities.

        Property and Equipment

        Property and  equipment is stated at cost.  Depreciation  is  calculated
        utilizing the  straight-line  method over the estimated  useful lives of
        the assets of three years.

        Purchased Software

        Pursuant to the provisions of SFAS No. 86,  "Accounting for the Costs of
        Computer Software to Be Sold, Leased or Otherwise Marketed,"  internally
        developed  software  and  software  purchased  from  third  parties  are
        capitalized  if the  related  software  product  under  development  has
        reached  technological  feasibility or if there are  alternative  future
        uses  for  the  purchased  software.  These  costs  are  amortized  on a
        product-by-product  basis typically over five years using the greater of
        the ratio that current gross revenue for a product bears to the total of
        current and  anticipated  future  gross  revenue for that product or the
        straight-line  method over the remaining  estimated economic life of the
        product.

        At each balance sheet date, the unamortized capitalized cost of computer
        software on a  product-by-product  basis is evaluated by comparing it to
        the net  realizable  value of that  product.  The  amount  by which  the
        unamortized  capitalized costs of a computer software product exceed its
        net  realizable  value is written  off.  Amortization  charges  were not
        incurred during the three and nine months ended September 30, 2003 since
        the Company is still in the development stage.

        Software License Rights

        Software  license rights are stated at cost. In accordance with SFAS No.
        142, "Goodwill and Other Intangible  Assets," the rights were determined
        to have a five year life and will be amortized  using the  straight-line
        method. Amortization charges were not incurred during the three and nine
        months  ended  September  30,  2003  since the  Company  is still in the
        development stage.


                                       12
<PAGE>

                                                          EMERGENSYS CORPORATION
                      (FORMERLY KNOWN AS MEDICAL LICENSING INTERNTATIONAL CORP.)
                                                   (A DEVELOPMENT STAGE COMPANY)
                                                                        CONTENTS
                                                  SEPTEMBER 30, 2003 (UNAUDITED)
--------------------------------------------------------------------------------


        Intangible Assets

        In accordance with Statement of Financial  Accounting Standards ("SFAS")
        No. 144,  "Accounting  for the  Impairment  or  Disposal  of  Long-Lived
        Assets", the Company evaluates long-lived assets,  including intangibles
        assets other than goodwill, for impairment when indicators of impairment
        are present and the undiscounted cash flows estimated to be generated by
        those  assets  are  less  then the  assets'  carrying  amounts.  Factors
        considered  important which could trigger an impairment  review include,
        but  are  not  limited  to,  significant  underperformance  relative  to
        expected  historical or projected future operating results,  significant
        changes  in the  manner  of use of the  assets or the  strategy  for the
        Company's overall business and significant negative industry or economic
        trends. If such assets are identified to be impaired,  the impairment to
        be  recognized  is the amount by which the  carrying  value of the asset
        exceeds the fair value of the asset.

        Loss per Share

        The Company  calculates  loss per share in accordance with SFAS No. 128,
        "Earnings  per Share."  Basic loss per share is computed by dividing the
        loss available to common shareholders by the weighted-average  number of
        common shares outstanding. Diluted loss per share is computed similar to
        basic loss per share except that the denominator is increased to include
        the number of additional  common shares that would have been outstanding
        if the  potential  common  shares had been issued and if the  additional
        common shares were dilutive.


                                       13
<PAGE>

                                                          EMERGENSYS CORPORATION
                      (FORMERLY KNOWN AS MEDICAL LICENSING INTERNTATIONAL CORP.)
                                                   (A DEVELOPMENT STAGE COMPANY)
                                                                        CONTENTS
                                                  SEPTEMBER 30, 2003 (UNAUDITED)
--------------------------------------------------------------------------------


NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

LOSS PER SHARE (CONTINUED)

        The  following  potential  common  shares  have been  excluded  from the
        computation  of  diluted  net loss per share for the nine  months  ended
        September 30, 2003 and 2002 because they are anti-dilutive:

<TABLE>
<CAPTION>
                                                        2003               2002
                                                      -----------       -----------
                                                      (unaudited)       (unaudited)
<S>                                                  <C>                <C>
        Warrants issued in private placement          3,200,000                 --
        Stock options                                        --          2,149,248
</TABLE>


        Estimates

        The  preparation  of financial  statements  requires  management to make
        estimates and assumptions that affect the reported amounts of assets and
        liabilities  and disclosure of contingent  assets and liabilities at the
        date of the financial statements and the reported amounts of revenue and
        expenses during the reporting  period.  Actual results could differ from
        those estimates.

        Recently Issued Accounting Pronouncements

        In April 2003, the Financial  Accounting Standards Board ("FASB") issued
        SFAS No. 149, "Amendment of Statement 133 on Derivative  Instruments and
        Hedging  Activities."  SFAS No. 149 amends and clarifies  accounting and
        reporting for derivative  instruments and hedging  activities under SFAS
        No. 133, "Accounting for Derivative Instruments and Hedging Activities."
        SFAS  No.  149 is  effective  for  derivative  instruments  and  hedging
        activities entered into or modified after September 30, 2003, except for
        certain forward purchase and sale securities. For these forward purchase
        and sale securities, SFAS No. 149 is effective for both new and existing
        securities after September 30, 2003. This statement is not applicable to
        the Company.

        In May 2003,  the FASB  issued  SFAS No.  150,  "Accounting  for Certain
        Financial  Instruments  with  Characteristics  of both  Liabilities  and
        Equity." SFAS No. 150 establishes standards for how an issuer classifies
        and measures in its statement of financial  position  certain  financial
        instruments  with  characteristics  of both  liabilities and equity.  In
        accordance  with  the  standard,   financial   instruments  that  embody
        obligations for the issuer are required to be classified as liabilities.
        SFAS No. 150 will be effective for financial instruments entered into or
        modified  after May 31,  2003 and  otherwise  will be  effective  at the
        beginning of the first  interim  period  beginning  after June 15, 2003.
        This statement is not applicable to the Company.


                                       14
<PAGE>

                                                          EMERGENSYS CORPORATION
                      (FORMERLY KNOWN AS MEDICAL LICENSING INTERNTATIONAL CORP.)
                                                   (A DEVELOPMENT STAGE COMPANY)
                                                                        CONTENTS
                                                  SEPTEMBER 30, 2003 (UNAUDITED)
--------------------------------------------------------------------------------



NOTE 4 - COMMITMENTS AND CONTINGENCIES

        Service Agreement

        On September 16, 2003, the Company entered into a service agreement with
        3720161 Canada Corporation,  a Canadian corporation doing business under
        the name of Mobilair Integration  ("Mobilair").  The Company will be the
        service  provider for  Mobilair in  connection  with a software  license
        agreement in order to design,  develop,  deploy,  and  maintain  certain
        software assets. The term of the contract is for six months,  commencing
        on October 1, 2003, for consideration of $100,000 per month. The Company
        will   provide  10  people  who  will  be   available  to  complete  all
        modifications to the software for sales around the world.

        The service  agreement also includes the purchase of a Web site,  design
        and conception of the product in different  languages,  worldwide market
        studies,  and translation and  documentation of the software in English,
        Spanish,  and  Portuguese.  The  Company  recorded  $140,000  in prepaid
        marketing,  $70,000 in property and equipment, and $780,000 in purchased
        software related to this contract.

NOTE 5 - SHAREHOLDERS' EQUITY

        In May 2003,  the Company  issued  5,500,000  shares of common stock for
        $100,000.

        Between July and September 2003, the received $1,600,000 in exchange for
        its  commitment  to  issue  6,400,000  units,  2,000,000  of  which  are
        committed to be issued to certain related  parties.  Each unit consisted
        of one share of the Company's common stock and a warrant to purchase one
        half share of the  Company's  common  stock.  Each full  warrant  has an
        exercise price of $0.375, vests immediately,  and expires two years from
        the date of issuance.

NOTE 6 - RELATED PARTY TRANSACTIONS

        The Company uses the services and some of the employees of an affiliated
        company and has its executive  offices at the offices of the  affiliate.
        The  Company  does not pay any  amount  to or for the  employees  of the
        affiliate  or any rent for these  offices.  The Company  reimburses  the
        affiliate for documented out-of-pocket expenses incurred on its behalf.



                                       15
<PAGE>
ITEM 2. MANAGEMENT'S  DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF  OPERATIONS/PLAN  OF OPERATION

The following  discussion  of our financial  condition and results of operations
should be read in  conjunction  with the financial  statements  and the notes to
those statements  included  elsewhere in this report.  In May 2003, we exchanged
all of the stock of our subsidiary  MoliChem R&D, Inc. for 13,355,282  shares of
our stock owned by Lantibio,  Inc., a company owned by the former  president and
certain  former  shareholders  of ours. As a result of the sale of Molichem R&D,
Inc., the financial data for the three and nine months ended  September 30, 2002
has been restated. We also received a non-execlusive license to develop, market,
and sell certain products  incorporating  MoliChem R&D, Inc.'s compounds Moli56A
and  Moli56B.  Prior to the  exchange,  all of our assets and  liabilities  were
transferred to MoliChem R&D, Inc. This sale of our operating  subsidiary brought
to an end our proposed business as a pharmaceutical company. Effective September
16, 2003,  the date we entered into a Software  License  Agreement  with 3720161
Canada Corporation (the "License  Agreement"),  we have devoted our resources to
the exploitation of the related license. Accordingly, the discussion below as it
relates to period to period comparisons is primarily of historical  significance
only.

We were incorporated in the state of Delaware on July 20, 1998 under the name of
Cortez Development, Ltd. ("Cortez"). Our name was changed to MoliChem Medicines,
Inc. on February 21, 2001,  following a reverse  merger  effected on January 18,
2001.  On January 18, 2001,  MoliChem  R&D,  Inc.  acquired  Cortez in a reverse
merger in which  Molichem R&D, Inc. was the  accounting  acquirer and Cortez was
the legal  acquirer.  MoliChem R&D, Inc. was  incorporated in the state of North
Carolina on December  21, 1995 under the name of MoliChem  Medicines,  Inc.  Its
name was changed to MoliChem R&D, Inc. on April 6, 2001. In  furtherance  of our
May 2003 sale of Molichem R&D, Inc., and our change in business  operations,  on
June 25,  2003 we changed  our name to  Medical  Licensing  International  Corp.
Further to the  execution  of the License  Agreement,  on  November  21, 2003 we
changed our name to EmergenSys  Corporation.  We have had no operating  revenues
since our inception.

CRITICAL ACCOUNTING POLICIES

Our discussion and analysis of our financial condition and results of operations
are based upon our financial statements,  which have been prepared in accordance
with  generally  accepted  accounting  principles  in  the  United  States.  The
preparation  of financial  statements  require  management to make estimates and
judgments that affect the reported amounts of assets and  liabilities,  revenues
and expense  and  disclosures  at the date of the  financial  statements.  On an
on-going basis, we evaluate our estimates,  including, but not limited to, those
related  to  revenue   recognition  and  impairment  of   intangibles.   We  use
authoritative pronouncements,  historical experience, belief of what could occur
in the future and other  assumptions as the basis for making  estimates.  Actual
results  could  differ  from  those  estimates.  We believe  that the  following
critical accounting policies affect our more significant judgments and estimates
in the  preparation  of our  consolidated  financial  statements.  We apply  our
estimates and judgments consistently for all periods presented.


                                       16
<PAGE>
Purchased Software

Pursuant to the provisions of SFAS No. 86, "Accounting for the Costs of Computer
Software  to Be  Sold,  Leased  or  Otherwise  Marketed,"  internally  developed
software  and  software  purchased  from third  parties are  capitalized  if the
related software product under development has reached technological feasibility
or if there are alternative future uses for the purchased software.  These costs
are amortized on a product-by-product  basis typically over five years using the
greater of the ratio that current gross revenue for a product bears to the total
of  current  and  anticipated  future  gross  revenue  for that  product  or the
straight-line method over the remaining estimated economic life of the product.

At each  balance  sheet  date,  the  unamortized  capitalized  cost of  computer
software on a  product-by-product  basis is evaluated by comparing it to the net
realizable  value  of  that  product.   The  amount  by  which  the  unamortized
capitalized costs of a computer software product exceed its net realizable value
is written off. Amortization charges were not incurred during the three and nine
months ended  September  30, 2003 since the Company is still in the  development
stage.

Intangible Assets

In accordance with Statement of Financial Accounting Standards ("SFAS") No. 144,
"Accounting  for the Impairment or Disposal of Long-Lived  Assets",  the Company
evaluates long-lived assets,  including  intangibles assets other than goodwill,
for impairment  when  indicators of impairment are present and the  undiscounted
cash flows  estimated  to be generated by those assets are less then the assets'
carrying amounts. Factors considered important which could trigger an impairment
review include, but are not limited to, significant underperformance relative to
expected  historical or projected future operating results,  significant changes
in the manner of use of the assets or the  strategy  for the  Company's  overall
business and significant  negative  industry or economic trends.  If such assets
are identified to be impaired,  the impairment to be recognized is the amount by
which the carrying value of the asset exceeds the fair value of the asset.

RESULTS OF OPERATIONS

For the three-month  periods ended September 30, 2003 and September 30, 2002, we
had total revenue of $0 and $430,533,  respectively.  For the nine-month periods
ended  September 30, 2003 and September 30, 2002, we had total revenue of $0 and
$1,297,875,  respectively.  The decrease in total revenue for the three and nine
month periods  ended  September 30, 2003 as compared to the three and nine month
periods ended September 30, 2002 was due to the December 2002 termination of our
agreement with InterMune,  Inc. for the joint development and  commercialization
of Moli901 and to the restatement related to the sale of Molichem R&D, Inc.

Our total  expenses for the  three-month  periods  ended  September 30, 2003 and
September 30, 2002 were $54,451 and $159,171,  respectively.  Our total expenses
were $78,730 for the nine-month period ended September 30, 2003 and $721,560 for
the nine-month  period ended  September 30, 2002. The decrease in total expenses
for the three and nine month periods ended September 30, 2003 as compared to the
three and nine month  periods  ended  September  30, 2002 was due to the scaling
back of our operations  during 2003 which resulted in lower personnel  expenses,
professional fees, and administrative and support expenses.


                                       17
<PAGE>


For the three-month  periods ended September 30, 2003 and September 30, 2002, we
had net losses of $54,541 and $527,857 or $.01 and $.03 per share, respectively.
For the nine-month periods ended September 30, 2003 and Sept 30, 2002 we had net
losses of $344,919 and $2,374,135 or $.02 and $.13 per share,  respectively.  We
attribute the losses for the three and nine month  periods  ended  September 30,
2003 to reorganization  costs.  During the nine month period ended September 30,
2003, we incurred non-recurring costs associated with discontinued operations of
$266,189.

LIQUIDITY AND CAPITAL RESOURCES

We have  incurred  losses  since the  inception  of our  business.  We have been
dependent on  acquisitions  and funding from  private  lenders and  investors to
conduct  operations.  As of September 30, 2003 we had an accumulated  deficit of
$2,015,154.  As of September 30, 2003,  we had total current  assets of $726,911
and total  current  liabilities  of  $50,000  or  positive  working  capital  of
$676,911.

During the three month  period  ended  September  30,  2003 we  obtained  equity
financing  of  $1,600,000.  These  sums were used to provide  financing  for our
activities related to the software license.

PLAN OF OPERATION

We were incorporated in the State of Delaware on July 20, 1998 under the name of
Cortez  Development  Ltd.  Our name was changed to Molichem  Medicines,  Inc. on
February 21, 2001, to Medical Licensing International Corp. on June 25, 2003 and
to EmergenSys  Corporation  on November 21, 2003.  We were a  development  stage
pharmaceutical company until the May 2003 sale of our then operating subsidiary,
Molichem R&D Inc.  Since  September 16, 2003,  the date of our Software  License
Agreement and our Service  Agreement  with 3720161 Canada  Corporation,  we have
devoted our financial and human  resources to the  development  and marketing of
the software products related to the software license.

Through  our service  agreement  with  3720161  Canada  Corporation,  a Canadian
corporation doing business as Mobilair  Integration,  we have been modifying the
software to make it adaptable for use in North America,  South America and other
markets.  The software  developed by Mobilair  Integration had been developed in
French solely for use in Quebec  Province.  To complete the  development  of our
proposed software  products related to the software  license,  engage in related
marketing  activities  and  conduct  general  business  operations,  we  will be
required to raise an estimated  $1,500,000  to  $2,000,000  over the next twelve
months. These proceeds will be used for:


                                       18
<PAGE>


        o       The    recruitment    and    training    of   a    network    of
                Value-Added-Resellers in the United States;

        o       The  formation of a small direct  marketing  team and a training
                team;

        o       The  hiring of  several  administrative  personnel  and  support
                staff;

        o       The  completion of our software  products for sale in the United
                States and internationally;

        o       The opening of one or two satellite offices; and

        o       General and administrative expenses.

We intend to achieve our required  financing through sales of our equity or debt
securities.  No assurance can be given that we will be successful in this regard
or that if  achieved,  we will do so on  favorable  terms.  Our failure to raise
funds as and when  needed  will  delay  our  ability  to  complete  our  product
development and marketing plans and achieve operating revenues.

We  expect  to add  five to ten  employees  over  the  next  twelve  months.  No
significant  research and  development  expenses are planned for the next twelve
months, nor are any major purchases of plant and equipment contemplated.

We believe that $1,500,000 to $2,000,000 of additional  capital will allow us to
operate for the next twelve months and engage in our planned activities. Most of
the product  development  related to the licensed technology has been completed.
We intend to enter into  sub-contracting  arrangements with Mobilair Integration
and others  with  respect to our  additional  technical  requirements.  After we
complete  our  initial  products  we will look to  complement  and expand  these
product offerings. Further licensing or acquisition of technologies will require
additional  funds.  Moreover,  if significant  orders are received over the next
twelve months,  additional funds could be required for accelerating our business
plan as well as  providing  funds  for  bonding  arrangements  that are  often a
condition of larger contracts.

ITEM 3.  CONTROLS AND PROCEDURES

Our principal  executive  officer and principal  financial officer evaluated the
effectiveness  of our disclosure  controls and procedures as of a date within 90
days prior to the filing of this report. Based on this evaluation, our principal
executive  officer and  principal  financial  officer  have  concluded  that our
controls and procedures are effective in providing reasonable assurance that the
information required to be disclosed in this report is accurate and complete and
has been recorded,  processed,  summarized  and reported  within the time period
required  for  the  filing  of  this  report.  Subsequent  to the  date  of this
evaluation, there have not been any significant changes in our internal controls
or, to our  knowledge,  in other  factors  that could  significantly  affect our
internal controls.


                                       19
<PAGE>


Consistent  with Section  10A(i)(2) of the  Securities  Exchange Act of 1934, as
added by Section 202 of the  Sarbanes-Oxley  Act of 2002, we are responsible for
listing  the  non-audit  services  approved  by our  Board  of  Directors  to be
performed by Singer  Lewak  Greenbaum & Goldstein  LLP,  our  external  auditor.
Non-audit  services  are  defined  as  services  other than  those  provided  in
connection with an audit or a review of our financial  statements.  Our Board of
Directors  currently has not approved the engagement of Singer Lewak Greenbaum &
Goldstein LLP to perform any non-audit services in 2003.

                           PART II--OTHER INFORMATION

ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS

Effective  September 16, 2003 we entered into a Software License  Agreement with
3720161 Canada Corporation, a Canadian corporation doing business under the name
of Mobilair Integration.  In consideration of the License Agreement, as amended,
we are obligated to issue an aggregate of 13,900,000  shares of our common stock
including 9,030,000 shares to Mobilair Integration; 3,810,000 shares to Dominion
Investments Ltd., an assignee of Mobilair  Integration;  and 1,000,000 shares to
certain  employees of Mobiliar  Integration.  The 13,900,000 shares have not yet
been  issued  but  are  expected  to be  issued  shortly.  For  purposes  of the
disclosure on the number of shares of our common stock outstanding, as set forth
on the cover of this  Quarterly  Report,  we are treating  these shares as being
issued and  outstanding.  The issuances of these shares will be made in reliance
on  Regulation  S under  the  Securities  Act of 1933,  as  amended,  and in one
instance, Section 4(2) under the Securities Act of 1933, as amended.

Effective  September  26, 2003 we completed a private  offering  whereby we sold
6,400,000  units at $.25  per unit or  $1,600,000  on an  aggregate  basis to 16
persons.  2,000,000 of the units were sold to  affiliates  of the Company.  Each
unit  consisted of one share of common stock and one half common stock  purchase
warrant.  Each full  warrant  entitles  the holder to purchase  one share of our
common  stock at a price of $.375 per  share for a period of two years  from the
date of issuance.  The 6,400,000 shares  subscribed for have not yet been issued
but are expected to be issued  shortly.  For purposes of the  disclosure  of the
number of shares of our common stock  outstanding,  as set forth on the cover of
this  Quarterly  Report,  we are  treating  these  shares  as being  issued  and
outstanding.  Sales to 14 of the  subscribers  were  made to non-US  persons  in
reliance on Regulation S under the Securities Act of 1933, as amended.  Sales to
2 of the subscribers were made to accredited US investors in reliance on Section
4(2) of the Securities Act of 1933, as amended.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

By consent, shareholders of record on September 16, 2003 holding an aggregate of
7,500,000 of our 10,824,005 then  outstanding  shares,  approved the form of and
filing of our Amended and Restated Certificate of Incorporation, which was filed
with the Delaware Secretary of State on November 21, 2003.


                                       20
<PAGE>


ITEM 5. OTHER INFORMATION

Effective  September  16, 2003 we entered into a Service  Contract  with 3720161
Canada   corporation,   a  Canadian   corporation  doing  business  as  Mobilair
Integration.   This   agreement  is  intended  to  enable  us  to  commence  the
exploitation  of  the  exclusive  software  license  related  to  public  safety
management systems granted to us by Mobilair  Integration.  The services covered
by this agreement include:

        o       website  design,   development,   maintenance  and  hosting;

        o       packaging of public safety  applications;

        o       worldwide  marketing  services;

        o       translation  of software into multiple  languages;

        o       design  and  conception  of  product   briefs  and   multi-media
                presentations;

        o       product localization for 30 countries; and

        o       document  translations,  including  system  documentation,  user
                manuals, and training manuals into multiple languages.

In consideration  for these services,  all of which are to be provided not later
than December 31, 2003, we paid $1,000,000 to Mobilair Integration.  Pursuant to
the Service  Contract,  for the six month period that commenced October 1, 2003,
we are also paying Mobilair Integration $100,000 per month for providing us with
the  services of 10 persons  with the  expertise,  capacity  and  experience  to
support our activities during this period. Among other things, these persons are
assisting  us with  making  certain of the  software  modifications  required to
enable us to sell the licensed product worldwide.

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K.

(a)     Exhibits

The following exhibits are filed as a part of this report on Form 10-QSB:

<TABLE>
<CAPTION>
EXHIBIT NO.                                   DESCRIPTION
<S>               <C>
3.1               Amended  and  Restated   Certificate   of   Incorporation   of
                  Registrant  as filed with the  Delaware  Secretary of State on
                  November 21, 2003 10.1  Amendment,  dated as of September  16,
                  2003 to Software  License  Agreement  between  Registrant  and
                  3720161 Canada Corporation

10.2              Service  Agreement  dated as of  September  16,  2003  between
                  Registrant   and   3720161   Canada   Corporation   31.1  Rule
                  13(a)-14(a)/15(d)-14(a)  Certification of Principle  Executive
                  Officer
</TABLE>


                                       21
<PAGE>

<TABLE>
<S>               <C>
31.2              Rule   13(a)-14(a)/15(d)-14(a)   Certification   of  Principle
                  Financial Officer

32.1              Rule 1350 Rule 1350Certification of Chief Executive Officer

32.2              Rule 1350 Certification of Chief Financial Officer
</TABLE>


(b) Reports on Form 8-K

On  September  30,2003  we filed a Form 8-K dated  September  16,  2003.  Item 5
thereof referred to the September 16, 2003 Software License Agreement between us
and 3720161 Canada Corporation and to changes in our board and management


                                       22
<PAGE>


                                   SIGNATURES


          Pursuant to the  requirements of Section 13 or 15(d) of the Securities
      Exchange Act of 1934,  the  Registrant has duly caused this Form 10-QSB to
      be signed on its behalf by the undersigned, thereunto duly authorized.

      Dated: December 17, 2003              EmergenSys Corporation

                                            By: /s/ Daniel Veilleux
                                                -----------------------
                                            Daniel Veilleux
                                            President, Chief Executive Officer



                                       23